Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "innovations"

332 News Found

Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune
Healthcare | February 07, 2025

Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune

This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being


Somaiya Vidyavihar University to host conference on ‘Clinical Translation of Biomaterials for Future Healthcare’
News | February 04, 2025

Somaiya Vidyavihar University to host conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications


Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
Policy | February 01, 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25


Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad
News | January 24, 2025

Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad

The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations


Bayer’s pharma growth strategy progressing well as pipeline advances
News | January 15, 2025

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid


Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
Clinical Trials | January 10, 2025

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients


Department of Biotechnology hosts webinar on biomanufacturing of enzymes
Biotech | December 28, 2024

Department of Biotechnology hosts webinar on biomanufacturing of enzymes

The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.